Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy
Status:
Recruiting
Trial end date:
2020-12-25
Target enrollment:
Participant gender:
Summary
Epidermal growth factor receptor inhibitor (EGFRI) therapy for cancer is associated with
potentially severe face and trunk skin acneiform rash. Severe or persistent side effects may
lead to decreased dose, interruption or discontinuation of EGFRI treatment. Inflammation is
believed to play an important role in EGFRI-induced skin toxicity as a number of
proinflammatory cytokines induced by EGFRI are released from epidermal cells, resulting in
activation and recruitment of immune cells such as neutrophils and lymphocytes, and
subsequent development of skin reaction associated with keratinocyte apoptosis. AC-701 has
been reported its antibiotic and anti-inflammatory activities in literature, and further
demonstrated in vitro effect to prevent the secretion of inflammatory cytokines associated
with EGFR inhibition. This study is to evaluate the prophylactic efficacy of topical AC-701
in subjects with skin rash associated with EGFRI therapy.